2-methyl-5-(2-methylpropyl)furan | 70390-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-methyl-5-(2-methylpropyl)furan
• 英文别名: 2-isobutyl-5-methyl-furan；2-Isobutyl-5-methylfuran
• CAS: 70390-90-8
• 化学式: C₉H₁₄O
• 分子量: 138.21
• InChiKey: XYKLSCVDLBZOEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-5-(2-methylpropyl)furan 在 sodium hydroxide 、 硫酸 、 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 反应 8.0h， 生成 2-{2-[乙基(甲基)氨基]乙基}-3-甲基-2-(1-萘基)丁醛
  参考文献：
  名称：

  Carr, Graham; Dean, Christopher; Whittaker, David, Journal of the Chemical Society. Perkin transactions II, 1989, p. 71 - 76

  摘要：

  DOI：
• 作为产物：
  描述：

  2-methyl-1-(5-methylfuran-2-yl)propan-1-one 在 氢氧化钾 、 一水合肼 作用下， 以 水 、 乙二醇 为溶剂， 反应 2.0h， 以12 g的产率得到2-methyl-5-(2-methylpropyl)furan
  参考文献：
  名称：

  Carr, Graham; Dean, Christopher; Whittaker, David, Journal of the Chemical Society. Perkin transactions II, 1989, p. 71 - 76

  摘要：

  DOI：

文献信息

• Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same
  申请人：Kim Seon Mi

  公开号：US20130137661A1

  公开（公告）日：2013-05-30

  Disclosed are compounds useful as gonadotrophin-releasing hormone (“GnRH”) receptor antagonist.

  披露了作为促性腺激素释放激素（“GnRH”）受体拮抗剂有用的化合物。
• Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning
  申请人：Johnson Alan T.

  公开号：US20100286125A1

  公开（公告）日：2010-11-11

  Compounds having the formula wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 4-phenyl-4-hydroxy-butyric acid and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.

  具有以下式的化合物是4-苯基-4-羟基丁酸的羟肟酸衍生物，能够抑制炭疽细菌感染的致命效应，并且在炭疽中毒的治疗中有用。
• GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：SK CHEMICALS CO., LTD.

  公开号：US20150166558A1

  公开（公告）日：2015-06-18

  Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

  揭示了一种促性腺激素释放激素受体拮抗剂和包括该拮抗剂的药物组合物，可用于预防或治疗与性激素相关的疾病，如子宫内膜异位症、闭经、月经不调、子宫肌瘤、子宫纤维瘤、多囊卵巢综合征、红斑狼疮、多毛症、性早熟、身材矮小、痤疮、脱发、性腺类固醇依赖性肿瘤、促性腺激素产生垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕症，以及阿尔茨海默病。
• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• [EN] COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE<br/>[FR] COMPOSITIONS ET PROCEDES LES UTILISANT POUR LE TRAITEMENT DE MALADIE NEURODEGENERATIVE ET MITOCHONDRIALE
  申请人：MITOKININ LLC

  公开号：WO2015123365A1

  公开（公告）日：2015-08-20

  The present disclosure is directed, in part, to compounds, or pharmaceutically acceptable salts thereof, for the treatment and/or prevention of neurodegenerative disease and/or mitchonodrial disease including Parkinson's disease and Leigh's disease.

  本公开涉及部分化合物或其药用盐，用于治疗和/或预防神经退行性疾病和/或线粒体疾病，包括帕金森病和雷氏病。